CHAMOT
喬默生物技術(上海)有限公司
CHAMOT BIOTECHNOLOGY CO. LTD.

转 染 试 剂
FectinMore™ Transfection Reagent

FectinMore™ Transfection Reagent

FectinMore™转染试剂是经优化设计的非脂质体阳离子聚合物 (Cationic Polymers) 转染试剂，采用阳离子聚合物介质递送核酸，该试剂与带负电的核酸形成带正电的复合物，能够与带负电的细胞膜表面接触，通过细胞内吞作用摄入细胞内，不会破坏靶细胞的细胞膜，因而毒性很低。

目标核酸与FectinMore™形成的复合物以包涵体的形式在胞质中迅速释放，并进一步进入细胞核内转录表达。脂质体复合物类似过程会受血清影响，实验中需更换无血清培养基，操作较FectinMore™费时。



产品特点

01 广谱高效的转染表现

在很多常用细胞系和部分原代细胞上的转染效率优于传统的脂质体转染试剂。

02 低细胞毒性

对细胞作用温和，转染后在较低的细胞 聚集水平下仍能实现高密度生长。

03 操作简单

新型阳离子聚合物与血清及抗生素兼容，无需更换培养液，节省大量实验时间。

Cell Lines	Efficiency(%GFP)	Best Records
293T	>90%	98%
BHK-21	>80%	96%
HuH-7	>75%	95%
HepG2	>75%	92%
Vero	>40%	82%
HMEC-1	>40%	65%
U118 MG	>25%	43%
SKNSH	>25%	58%
CHO-K1	>70%	90%
MDCK	>65%	79%

转染效率 ▲

293T	HepG2	PBMCs
A549	HMEC-1	S2
BHK-21	HT-29	SF9
C6/36	HuH-7	SKNSH
CHO-K1	HUVEC	SP2/0
DLBCL	K562	THP-1
ES-2	MDCK	U118MG
HCT116	Ovarian cancer cells	Vero
HeLa	P3X63Ag8	more.....

验证细胞系 ▲

www.chamot-bio.com
864920491
021-51880030
chamot_bio@163.com

CHAMOT
喬默生物技術(上海)有限公司
CHAMOT BIOTECHNOLOGY CO. LTD.

数据表现

The targeted DNA can be transfected to different cells efficiently by Chamot's DNA transfection reagent.

Cells transfected with DNA transfection reagent. Reagent and plasmid at a 3:1 reagent: DNA ratio. Proteins expression checked two day post-transfection.

Proteins expression checked by western blot in specific primary antibody followed by secondary antibody (anti-Mouse (H+L)-HRP).



Proteins expression checked by FACS in specific primary antibody followed by secondary antibody (anti-Mouse (H+L)-FAM).



Proteins expression checked by immunofluorescence (IFA) in specific primary antibody followed by secondary antibody (anti-Mouse IgG-iFluor 594).

产品列表

品号	品名	规格
CM001-0.75T	FectinMore™ Transfection Reagent	750 µL/vial
CM001-1.5T		1.5ml / vial
CM001-7.5T		5*1.5ml/vial
CM001-15T		10*1.5 ml /vial
CM001-30T		20*1.5ml/vial

MORE...

部分引用文献

Vitamin D-Binding Protein Enhances Epithelial Ovarian Cancer Progression by Regulating the Insulin-like Growth Factor-1/Akt Pathway and Vitamin D Receptor Transcription. Clin Cancer Res. 2018 Jul 1;24(13):3217-3228.***(IF 10.107)***

Pancreatic stellate cells activated by mutant KRAS-mediated PAI-1 upregulation foster pancreatic cancer progression via IL-8.Theranostics. 2019; 9(24): 7168–7183.***(IF 8.579)***

TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma. Molecular Oncology. 21 January 2020, Pages 928-945.***(IF 6.574)***

Macrophage migration inhibitory factor has a permissive role in concanavalin A-induced cell death of human hepatoma cells through autophagy. Cell Death & Disease. 2015 Dec 3;6:e2008.***(IF 6.304)***

TARBP2-Enhanced Resistance during Tamoxifen Treatment in Breast Cancer.Cancers. 2019, 11(2), 210.***(IF 6.126)***

www.chamot-bio.com 864920491 021-51880030 chamot_bio@163.com